Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INI-4001 in Advanced Solid Tumors
NCT06302426Phase 1Completed
- Sponsor
- Inimmune Corporation
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of INI-4001 in solid tumor (advanced stage) (6 arms), sponsored by Inimmune Corporation. Primary endpoint: Incidence of dose-limiting toxicities. Started Jul 2024; status: completed.
02
Drugs
INI-4001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06302426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06302426.